One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM). Here, we present the real-world use of mavacamten in 50 patients with oHCM at a tertiary car...

Full description

Bibliographic Details
Main Authors: Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Yaanik B. Desai, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Marco V. Perez, Masataka Kawana, Karim I. Sallam, Chad S. Weldy, Matthew T. Wheeler, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
mavacamten
MYK-461
hypertrophic cardiomyopathy
cardiac myosin inhibitor
hypertrophic cardiomyopathy with obstruction (oHCM)
hypertrophic obstructive cardiomyopathy (HOCM)
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1429230/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1429230/full

Similar Items